Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical Business ReviewThe application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Business Review The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. RegulatoryOncologyRead full story Post navigation Previous: Eli Lilly doubles down on in vivo with $7bn Kelonia buyoutNext: FDA kicks off review of Roche’s Gazyva for wider lupus use Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026